BioMarin Pharmaceutical has struck a deal to purchase fellow biotechnology firm Amicus Therapeutics for about $4.8 billion in money.
Source link
BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion
Related Posts
41% of Schools Report AI Cyber Incidents
A brand new research reveals 41% of faculties within the U.S. and U.K. have skilled AI-related cyber incidents, highlighting gaps…
A Gene Editing Therapy Cut Cholesterol Levels by Half
In a step towards the broader use of gene enhancing, a therapy that makes use of Crispr efficiently slashed excessive…
Tesla Loses Its EV Crown to BYD as Sales Keep Dropping
In contrast to Elon Musk along with his record of broken promises, the stats don’t lie. Tesla has misplaced the…